A groundbreaking new dietary approach may offer hope for individuals suffering from Crohn's disease. Recent research has shown that a short-term intermittent calorie-restrictive diet can lead to notable improvements in both symptoms and biological markers associated with mild-to-moderate Crohn's disease (CD). This study, conducted in the United States, reveals that participants who adhered to this specific eating regimen experienced significant enhancements in their physical well-being in just three months.
What makes this diet particularly intriguing is its simplicity: it involves calorie restriction only for five days each month. Participants who engaged in this fasting mimicking diet (FMD) demonstrated remarkable results, achieving higher rates of clinical response and remission compared to those following their regular dietary habits.
In this carefully controlled clinical trial, 100 participants were randomly assigned to either follow the FMD or continue with their standard diet over a span of three months. Researchers monitored changes in the Crohn's Disease Activity Index (CDAI) and levels of inflammatory biomarkers between the two groups.
The results were striking: almost 70% of the individuals on the FMD achieved a clinical response, characterized by a decrease in CDAI by at least 70 points, while fewer than 44% of those in the control group saw similar improvements. Additionally, around 65% of the FMD group reached clinical remission, defined as a CDAI of 150 or lower after completing the third cycle of the diet, compared to just 38% in the control group.
The FMD involved consuming 700 to 1100 calories daily for a consecutive five-day period each month, followed by a return to a standard diet for the remainder of the month. During the calorie-restricted days, participants were provided with plant-based meals.
Significantly, there was a marked reduction in faecal calprotectin, a biomarker indicative of inflammation, at the conclusion of the third diet cycle. The FMD group experienced an average decrease of 22%, whereas the control group saw an increase of 8%. Remarkably, nearly 40% of those on the FMD recorded a reduction in faecal calprotectin by 50% or more, in stark contrast to only 6% in the control cohort.
The study also noted a slight mean reduction in C-reactive protein levels in the FMD group (down by 1%), while the control group experienced a significant increase of 37%. Although this difference approached statistical significance, it fell just short (P = 0.06). Furthermore, there was no notable difference in erythrocyte sedimentation rates between the two groups.
Professor Sidhartha Sinha, a senior author and assistant professor of gastroenterology and hepatology at Stanford University, expressed their astonishment at the positive impact of the diet, stating, "We were very pleasantly surprised that the majority of patients seemed to benefit from this diet. We noticed that even after just one FMD cycle, there were clinical benefits."
The authors acknowledged the challenges inherent in studying dietary interventions, primarily due to the reliance on self-reported data and the inability to blind participants. Nevertheless, this trial succeeded in demonstrating reductions in objective inflammation markers alongside symptom improvement.
Interestingly, less than half of the control group reported symptom improvements, which researchers attribute to natural fluctuations in Crohn's disease symptoms and the effectiveness of their standard treatments and medications. After a three-month washout period following the third FMD cycle, clinical responses and remission rates appeared similar between both groups.
This loss of response raises questions about how many cycles of the FMD are necessary to sustain clinical benefits over time, suggesting that continued cycles may be essential for long-term remission, as emphasized by the researchers.
When looking at the data for mild CD patients, those on the FMD had a greater clinical response (75% versus 48% in the control group), and similar trends were observed among moderate CD patients (57% compared to 11%). Additionally, participants with colonic disease experienced a higher rate of clinical response when following the FMD (82% against 33% in the control group), as did those with ileocolonic disease (71% versus 30%). However, those with isolated ileal disease showed no such advantage (56% for FMD versus 60% for control).
Interestingly, the FMD also proved more effective for participants not undergoing any medical therapy, achieving a clinical response rate of 77% compared to 33% in the control group.
During the study, participants had an average age of 45 years, with around 40% of both groups classified as having an overweight BMI. The control group included a higher percentage of participants dealing with obesity (31% versus 15% in the FMD group) and had fewer females (56% compared to 80% in the FMD group).
Despite monitoring for any potential need for therapy escalation, such as the initiation of corticosteroid treatment or adjustments in advanced therapy dosing, there were no significant differences noted between the two groups throughout the duration of the study (28% in the FMD group versus 25% in the control).
While some participants in the FMD group reported experiencing fatigue and headaches during the study, it is noteworthy that there were no serious side effects reported across all participants.
This revolutionary research, published in Nature Medicine on January 13, 2026, opens new avenues for dietary strategies in managing Crohn's disease and invites further discussion on the implications of such findings for patient care.
